Immune responses to human cancer stem-like cells/cancer-initiating cells.
Immune responses to human cancer stem-like cells/cancer-initiating cells.
复制标题
DOI：
10.1111/cas.12830
复制
发表时间：
2016-01
期刊：
影响因子：
5.7
通讯作者：
Sato N
中科院分区：
文献类型：
--
作者：
Hirohashi Y;Torigoe T;Tsukahara T;Kanaseki T;Kochin V;Sato N
癌症干细胞样细胞（CSC）/癌症起始细胞（CIC）定义为具有较高肿瘤起始能力、自我更新能力和分化能力的癌细胞的次要亚群。近年来的研究表明，CSC/CIC对化疗、放疗和分子靶向治疗等常规肿瘤治疗具有一定的抵抗力，因此，CSC/CIC的放射治疗是治疗肿瘤的关键。癌症免疫治疗有望成为“第四种”癌症疗法。细胞毒性T淋巴细胞（CTL）在癌症免疫应答中起重要作用，并且CTL可以以抗原特异性方式识别CSC/CIC。CSC/CIC表达多种肿瘤相关抗原（TAA），并且癌症睾丸（CT）抗原是CSC/CIC靶向免疫治疗的合理来源。在这篇综述文章中，我们讨论了CTL对CSC/CIC的识别，CSC/CIC对免疫系统的调节，CSC/CIC中的TAA表达，以及CSC/CIC靶向免疫治疗的优势。
Cancer stem‐like cells (CSC)/cancer‐initiating cells (CIC) are defined as minor subpopulations of cancer cells that are endowed with properties of higher tumor‐initiating ability, self‐renewal ability and differentiation ability. Accumulating results of recent studies have revealed that CSC/CIC are resistant to standard cancer therapies, including chemotherapy, radiotherapy and molecular targeting therapy, and eradiation of CSC/CIC is, thus, critical to cure cancer. Cancer immunotherapy is expected to become the “fourth” cancer therapy. Cytotoxic T lymphocytes (CTL) play an essential role in immune responses to cancers, and CTL can recognize CSC/CIC in an antigen‐specific manner. CSC/CIC express several tumor‐associated antigens (TAA), and cancer testis (CT) antigens are reasonable sources for CSC/CIC‐targeting immunotherapy. In this review article, we discuss CSC/CIC recognition by CTL, regulation of immune systems by CSC/CIC, TAA expression in CSC/CIC, and the advantages of CSC/CIC‐targeting immunotherapy.